• 26 Feb 21

  Anagrelide Project Update

• 26 Feb 21

  Appendix 4D & Interim Financial Half Year Report FY2021

• 16 Feb 21

  Change of Director’s Interest Notice

• 16 Feb 21

  Change of Director’s Interest Notice

• 16 Feb 21

  Change of Director’s Interest Notice

• 16 Feb 21

  Appendix 2A

• 16 Feb 21

  Zelira Therapeutics Feasibility Study Update